IBO - יחס שווי חברה לקצב צמיחת הרווח Impact BioMedical, Inc.

Impact BioMedical Inc generates stable income based on the licensing of bioprotective patents, which minimizes costs. The price-to-earnings ratio relative to the EPS growth forecast confirms this trend, where the parameter value equals 0.00. A neutral geopolitical backdrop protects the business from sanctions, while outsourcing production and testing to external contractors allows the company to remain a pure-play research center.

The PEG ratio compares the P/E multiple with net income growth to determine whether a business valuation is fair relative to its expansion. By analyzing the P/E growth potential metric, an investor can identify asset undervaluation, which for Impact BioMedical Inc. (IBO) is driven by the implementation of robotic screening that accelerates product commercialization while optimizing operational personnel costs.